Understanding the Market | AKESO rises over 3% again as institutions expect the company's medical insurance coverage to further drive product sales growth

Zhitong
2025.04.02 03:29

AKESO rose over 3% again, with a cumulative increase of over 30% in the past six trading days. As of the time of writing, it rose 2.67% to HKD 3.08, with a trading volume of HKD 17.76 million. CMB International released a research report stating that AKESO's performance last year and in the second half of last year exceeded expectations. The company's product sales saw strong growth last year, and the firm expects that the group's medical insurance coverage will drive further sales growth this year and achieve breakeven. The firm noted that as the overseas registration research of Ivosidenib enters the sprint stage, more new antibody, ADC, and autoimmune candidates are entering clinical development, continuously enhancing the value of the company's pipeline. Citigroup pointed out that AKESO's product sales revenue in 2024 is expected to be RMB 2 billion, a year-on-year increase of 25%. It anticipates that the rapid volume increase of Cadonilimab and Ivosidenib after being included in the national medical insurance drug list will promote the commercialization process, along with the key data disclosure of Ivosidenib, leading to accelerated sales growth this year. Huatai Securities believes that the company's fundamentals are outstanding, with core products included in medical insurance and new indications gradually approved, which is expected to achieve sales growth. Additionally, the core pipeline has strong global potential, with multiple new drugs entering the clinical stage, solidifying the foundation for development

According to Zhitong Finance APP, AKESO (09926) has risen over 3% again, with a cumulative increase of over 30% in the past six trading days. As of the time of writing, it has risen 2.67%, priced at HKD 3.08, with a trading volume of HKD 17.76 million.

China Merchants International released a research report stating that AKESO's performance last year and in the second half of last year exceeded expectations. The company's product sales saw strong growth last year, and the bank expects that the group's medical insurance coverage will drive further sales growth this year, achieving breakeven. The bank noted that as the overseas registration research of Ivorcitin enters the final stage, more new antibodies, ADCs, and autoimmune candidates are entering clinical development, continuously enhancing the value of the company's pipeline.

Citigroup pointed out that AKESO's product sales revenue for 2024 is expected to be RMB 2 billion, a year-on-year increase of 25%. Looking ahead, the inclusion of Cardonilumab and Ivorcitin in the national medical insurance drug list is expected to lead to rapid sales growth, driving the commercialization process. Additionally, with the key data disclosure of Ivorcitin, sales growth is expected to accelerate this year. Huatai Securities believes that the company's fundamentals are outstanding, with core products included in medical insurance and new indications gradually approved, which is expected to achieve sales growth. The core pipeline has strong global potential, with multiple new drugs entering the clinical stage, solidifying the foundation for development

Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.